INCB 19602

Drug Profile

INCB 19602

Alternative Names: INCB019602; INCB19602

Latest Information Update: 24 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Incyte Corporation
  • Class Antihyperglycaemics
  • Mechanism of Action GPR109A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 31 May 2008 Phase-II clinical trials in Type-2 diabetes mellitus in USA (PO)
  • 30 Apr 2008 Incyte completes phase I trials in Type-2 diabetes in USA
  • 08 Jan 2008 Phase-I clinical trials in Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top